daclizumab + methotrexate (3S Guojian Pharmaceutical)

Jian Nipai + methotrexate (daclizumab + methotrexate) is an immunosuppressive combination regimen evaluated for the prophylaxis of graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Daclizumab (Jian Nipai / Xenopax) is a recombinant humanized monoclonal antibody that targets the alpha subunit of the interleukin-2 receptor (CD25) on activated T lymphocytes, thereby blocking IL-2-mediated T-cell activation and proliferation. Methotrexate is a folate analog metabolic inhibitor that reversibly inhibits dihydrofolate reductase (DHFR), leading to the depletion of tetrahydrofolates required for purine and thymidylate synthesis, which selectively suppresses rapidly dividing cells such as activated T-cells. Together, this combination regimen is designed to prevent acute GVHD while managing transplant-related complications.